Figure 2
From: Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs
Dependence of NF-κB response on type and dose of treatment. A-C (upper panels): Reporter SW480, wild-type HCT116, and p53-null HCT116 colon cancer cells were treated with decreasing concentrations of the cytokine, TNFα. The activation of NF-κB is presented as fold change in RLU compared to the control (none). A-C (lower panels): The reporter cells were treated with vehicle (DMSO), 5-FU (10 μM), CPT (1 μM), oxaliplatin (10 μM), phleomycin (200 μg/ml), or erlotinib (20 μM). The NF-κB activation index at 24 hours after treatment is shown. The cell lines responded differently to these clinically relevant drugs.